Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2012

View Archived Issues

New inhibitors of V600E-mutant B-raf presented

Chugai presents new highly potent and selective AXL inhibitor

Pozen discusses FDA meeting on integrated aspirin therapy NDA

Bristol-Myers Squibb halts development of candidate hepatitis drug

JAK inhibitor reduces signs and symptoms of arthritis in phase III trials

Novel PET tracer for tau imaging shows promise in vivo

Zyclara approved in Europe

Updated results from EMILIA study of trastuzumab emtansine

Novartis reports new mTOR/PI3K inhibitors

Collaborating organizations in France design new candidate drugs for parasitic diseases

Novel beta1-adrenoceptor ligands developed in U.K.

FDA issues refuse to file letter for Lemtrada sBLA

New everolimus formulation approved in Japan

Data reported from TRILOGY ACS trial of prasugrel

Abbott presents discovery of multiple HCV NS5B inhibitors

Seattle Genetics kicks off new study in renal cell carcinoma

Ten-gene molecular signature predicts response to cancer radiotherapy

Baxter to discontinue manufacturing Gammagard product

Plavix approved for STEMI in Japan

Lilly reports topline phase III results in Alzheimer's disease

NICE issues draft guidance on product for stroke

GSK and Theravance complete phase III COPD program

Strattera approved in Japan for adult ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...